MS RESEARCH AUSTRALIA TRIALS
Pharmaceutical company Sanofi have advised that their MS disease modifying therapy Aubagio will be delisted from the Australian market from October 2021.
Australian researchers and disease-based charities are working together to promote and simplify access to evidence-based stem cell therapies in Australia.
The FDA’s Letter of Support will stimulate studies that advance development and validation of Nfl as a biomarker to speed clinical trials in progressive MS.
MS Research Australia is currently funding 62 research projects covering a range of MS research priorities, including causes and prevention, better treatments and reversal of disability through repair or regeneration of cells.
Today is Clinical Trials Day and we would like to raise awareness of the importance of clinical trials and research in Australia, New Zealand, and around the world. We would also like to spotlight the vital role that clinicians and researchers play in conducting this life-changing research.
New Australian research showcases the continuing work of the Australian MS Longitudinal Study (AMSLS) investigating dietary habits and employment outcomes.
Additional medical conditions can worsen MS symptoms and are an important target for intervention to improve quality of life for people with MS